Vontobel Holding Ltd. Sells 18,760 Shares of Biogen Inc. $BIIB

Vontobel Holding Ltd. reduced its position in Biogen Inc. (NASDAQ:BIIB) by 48.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 19,988 shares of the biotechnology company’s stock after selling 18,760 shares during the quarter. Vontobel Holding Ltd.’s holdings in Biogen were worth $2,800,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Elevation Point Wealth Partners LLC acquired a new stake in Biogen in the second quarter valued at about $25,000. Rothschild Investment LLC increased its position in Biogen by 64.7% in the 2nd quarter. Rothschild Investment LLC now owns 224 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 88 shares during the period. Concord Wealth Partners increased its holdings in Biogen by 100.0% in the second quarter. Concord Wealth Partners now owns 228 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 114 shares during the period. NewSquare Capital LLC raised its position in shares of Biogen by 134.6% during the second quarter. NewSquare Capital LLC now owns 244 shares of the biotechnology company’s stock worth $31,000 after acquiring an additional 140 shares during the last quarter. Finally, WFA of San Diego LLC acquired a new stake in Biogen during the 2nd quarter valued at approximately $32,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

Biogen Stock Performance

NASDAQ:BIIB opened at $177.08 on Friday. The business’s fifty day moving average is $166.86 and its 200 day moving average is $146.71. Biogen Inc. has a 52-week low of $110.04 and a 52-week high of $185.17. The firm has a market cap of $25.98 billion, a price-to-earnings ratio of 16.14, a PEG ratio of 1.48 and a beta of 0.13. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.04 and a current ratio of 2.72.

Biogen (NASDAQ:BIIB) last released its quarterly earnings data on Thursday, October 30th. The biotechnology company reported $4.81 EPS for the quarter, beating analysts’ consensus estimates of $3.89 by $0.92. The company had revenue of $2.53 billion during the quarter, compared to analyst estimates of $2.34 billion. Biogen had a net margin of 15.98% and a return on equity of 14.13%. Biogen’s revenue was up 2.8% compared to the same quarter last year. During the same period last year, the business earned $4.08 earnings per share. Biogen has set its FY 2025 guidance at 14.500-15.00 EPS. Research analysts predict that Biogen Inc. will post 15.83 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the company. Tudor Pickering set a $157.00 price objective on Biogen in a research report on Monday, November 3rd. Needham & Company LLC restated a “hold” rating on shares of Biogen in a report on Wednesday, September 24th. William Blair restated an “outperform” rating on shares of Biogen in a report on Wednesday, September 24th. Citigroup reissued a “neutral” rating on shares of Biogen in a research report on Wednesday, September 24th. Finally, HSBC reissued a “reduce” rating and issued a $143.00 price objective (down previously from $144.00) on shares of Biogen in a research report on Wednesday, December 10th. Ten equities research analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $183.08.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.